Turtle Creek Wealth Advisors LLC Buys 11,092 Shares of Astrazeneca Plc $AZN

Key Points

• Turtle Creek Wealth Advisors LLC boosted its stake in AstraZeneca by 19.2%, buying 11,092 shares to hold 68,841 shares worth about $6.33 million at the end of the quarter.
• The company recently paid a $1.595 dividend to shareholders of record on Feb. 20 (paid Mar. 23), which the article reports as a 156.0% yield.
• Analyst coverage is mixed but overall positive: eight analysts rate AZN a Buy and one a Sell, giving an average rating of "Moderate Buy" and an average target price reported at $102.67.

Turtle Creek Wealth Advisors LLC lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN - Free Report) by 19.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,841 shares of the company's stock after purchasing an additional 11,092 shares during the period. Turtle Creek Wealth Advisors LLC's holdings in Astrazeneca were worth $6,329,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Triumph Capital Management bought a new stake in shares of Astrazeneca during the 3rd quarter worth $25,000. Bangor Savings Bank raised its stake in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company's stock worth $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC bought a new stake in shares of Astrazeneca during the 4th quarter worth $30,000. Rakuten Investment Management Inc. bought a new stake in shares of Astrazeneca during the 3rd quarter worth $31,000. Finally, YANKCOM Partnership bought a new stake in shares of Astrazeneca during the 4th quarter worth $31,000. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $192.35 on Friday. Astrazeneca Plc has a 12 month low of $132.32 and a 12 month high of $212.71. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The stock has a market cap of $298.31 billion, a PE ratio of 33.13, a price-to-earnings-growth ratio of 1.47 and a beta of 0.35.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were issued a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca's dividend payout ratio is 74.83%.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent analyst reports. TD Cowen reiterated a "buy" rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Wall Street Zen cut Astrazeneca from a "buy" rating to a "hold" rating in a research note on Saturday, April 4th. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Astrazeneca in a research note on Friday, February 6th. Weiss Ratings initiated coverage on Astrazeneca in a research note on Wednesday, March 11th. They issued a "buy (b)" rating on the stock. Finally, Barclays restated an "overweight" rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $102.67.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.